-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bronchopulmonary dysplasia is prevalent in very preterm infants, accounting for approximately 50% of surviving infants, and preterm birth, mechanical ventilation, oxygen exposure, and inflammation are important factors in bronchopulmonary dysplasia in preterm infants
We investigated the effects of hydrocortisone treatment on lung development, neurodevelopment, and survival in preterm infants with bronchopulmonary dysplasia after the second week of life
Differences in efficacy and safety endpoints between groups
Differences in efficacy and safety endpoints between groupsIn preterm infants with bronchopulmonary dysplasia , treatment with hydrocortisone from days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did 2-year neurodevelopmental outcomes between groups Significant difference
In preterm infants with bronchopulmonary dysplasia, treatment with hydrocortisone starting from postnatal days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did the 2-year neurodevelopmental outcomes differ significantly between groups
.
In preterm infants with bronchopulmonary dysplasia, treatment with hydrocortisone starting from postnatal days 14 to 28 did not improve survival without moderate to severe bronchopulmonary dysplasia, nor did the 2-year neurodevelopmental outcomes differ significantly between groups
.
Original Source:
Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia.
Leave a comment here